Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): A prospective, randomised, open-label, blinded-endpoint crossover trial

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 7, 2014, Pages 553-561

  Pedersen Bjergaard, Ulrik ^a,b   Kristensen, Peter Lommer ^a,c   Beck Nielsen, Henning ^d,e   Nørgaard, Kirsten ^f   Perrild, Hans ^g   Christiansen, Jens Sandahl ^h,i   Jensen, Tonny ^j   Hougaard, Philip ^e   Parving, Hans Henrik ^i,j   Thorsteinsson, Birger ^a,b   Tarnow, Lise ^a,c,i  

^a HILLERØD HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c STENO DIABETES CENTER   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^f HVIDOVRE HOSPITAL   (Denmark)

^g BISPEBJERG HOSPITAL   (Denmark)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ AARHUS UNIVERSITY   (Denmark)

^j Rigshospitalet   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; ISOPHANE INSULIN; ANTIDIABETIC AGENT; INSULIN; LONG ACTING INSULIN;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DENMARK; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 1; MIDDLE AGED; RISK FACTOR; SECONDARY PREVENTION;

CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN ASPART; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SECONDARY PREVENTION;

EID: 84903792623     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70073-7     Document Type: Article

References (31)

1. Lorber D, Anderson J, et al. Diabetes and driving. Diabetes Care 2012, 35(suppl 1):S8-86. American Diabetes Association.
2. McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 2012, 35:1897-1900.
3. Cox DJ, Irvine A, Gonder-Frederick L, Nowacek G, Butterfield J Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care 1987, 10:617-621.
4. Pramming S, Thorsteinsson B, Bendtson I, Binder C Symptomatic hypoglycaemia in 411 type 1 diabetic patients. Diabet Med 1991, 8:217-222.
5. Jørgensen HV, Pedersen-Bjergaard U, Rasmussen AK, Borch-Johnsen K The impact of severe hypoglycemia and impaired awareness of hypoglycemia on relatives of patients with type 1 diabetes. Diabetes Care 2003, 26:1106-1109.
6. Cryer PE The barrier of hypoglycemia in diabetes. Diabetes 2008, 57:3169-3176.
7. The effect of intensive therapy of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. The Diabetes Control and Complications Trial Research Group.
8. Macleod KM, Hepburn DA, Frier BM Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med 1993, 10:238-245.
9. ter Braak EW, Appelman AM, van der Laak M, Stolk RP, van Haeften TW, Erkelens DW Clinical characteristics of type 1 diabetic patients with and without severe hypoglycemia. Diabetes Care 2000, 23:1467-1471.
10. Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S, Hougaard P, Thorsteinsson B Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus. Lancet 2001, 357:1248-1253.
11. Pedersen-Bjergaard U, Pramming S, Heller SR, et al. Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev 2004, 20:479-486.
12. Donnelly LA, Morris AD, Frier BM, et al. Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med 2005, 22:749-755. for the DARTS/MEMO Collaboration.
13. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007, 50:1140-1147. UK Hypoglycaemia Study Group.
14. Kristensen PL, Hansen LS, Jespersen MJ, et al. Insulin analogues and severe hypoglycaemia in type 1 diabetes. Diabetes Res Clin Pract 2012, 96:17-23.
15. Weinstock RS, Xing D, Maahs DM, et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange Clinic Registry. J Clin Endocrinol Metab 2013, 98:3411-3419. for the T1D Exchange Clinic Network.
16. Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006, 2. CD003287.
17. Monami M, Marchionni N, Mannucci E Long-acting insulin analogues vs NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab 2009, 11:372-378.
18. Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009, 180:385-397.
19. Hansson L, Hedner T, Dahlöf B Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Blood Press 1992, 1:113-119.
20. Kristensen PL, Pedersen-Bjergaard U, Beck-Nielsen H, et al. A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna Trial): study rationale and design. BMC Endocrine Disorders 2012, 12:10.
21. Pedersen-Bjergaard U, Pramming S, Thorsteinsson B Recall of severe hypoglycaemia and self-estimated state of awareness in type 1 diabetes. Diabetes Metab Res Rev 2003, 19:232-240.
22. Høi-Hansen T, Pedersen-Bjergaard U, Thorsteinsson B Classification of hypoglycemia awareness in people with type 1 diabetes in clinical practice. J Diabetes Complications 2010, 24:392-397.
23. Defining and reporting hypoglycemia in diabetes. Diabetes Care 2005, 28:1245-1249. American Diabetes Association Workgroup on Hypoglycemia.
24. Bulsara MK, Holman CD, Davis EA, Jones TW Evaluating risk factors associated with severe hypoglycaemia in epidemiology studies-what method should we use?. Diabet Med 2004, 21:914-919.
25. Cryer PE Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes 2005, 54:3592-3601.
26. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004, 47:622-629.
27. Ferguson SC, Strachan MW, Janes JM, Frier BM Severe hypoglycaemia in patients with type 1 diabetes and impaired awareness of hypoglycaemia: a comparative study of insulin lispro and regular human insulin. Diabetes Metab Res Rev 2001, 17:285-291.
28. Heller SR, Macdonald IA, Herbert M, Tattersall RB Influence of sympathetic nervous system on hypoglycaemic warning symptoms. Lancet 1987, 330:359-363.
29. Guidance for industry. Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention US Department of Health and Human Services, Food and Drug AdministrationFood and Drug Administration, Center for Drug Evaluation and Research (CDER)Center for Drug Evaluation and Research (CDER), (accessed Jan 7, 2013). http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071624.pdf.
30. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus European Medicines Agency, (accessed Jan 7, 2013). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf.
31. Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012, 379:1489-1497. for the BEGIN Basal-Bolus Type 1 Trial Investigators.